Skip to main content

Ph-Positive Acute Lymphoblastic Leukemia: Dasatinib/Blinatumomab Effective in Phase 2

Positive survival outcomes were observed in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when treated with dasatinib followed by blinatumomab in in a phase 2 study now published in the New England Journal of Medicine. For the trial, adults with newly diagnosed Ph-positive ALL were given a seven-day prephase treatment with a glucocorticoid prior to the first administration of dasatinib in a 140 mg dose. Glucocorticoids were continued for 24 more days...

Continue reading